Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
McKesson
Harvard Business School
Moodys
Johnson and Johnson

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Patent: 9,375,496

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for Patent: 9,375,496
Title:Halogenated compounds for cancer imaging and treatment and methods for their use
Abstract: Compounds having a structure of Formula I: ##STR00001## or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X.sup.1, X.sup.2, X.sup.3 and X.sup.4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or .sup.123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
Inventor(s): Andersen; Raymond John (Vancouver, CA), Banuelos; Carmen Adriana (Richmond, CA), Garcia Fernandez; Javier (Colunga, ES), Imamura; Yusuke (Chiba, JP), Kunzhong; Jian (Vancouver, CA), Mawji; Nasrin R. (Burnaby, CA), Sadar; Marianne Dorothy (West Vancouver, CA), Wang; Jun (Surrey, CA), Tien; Amy (Hsing Chen) (Vancouver, CA)
Assignee: British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA)
Application Number:14/481,727
Patent Claims:see list of patent claims

Details for Patent 9,375,496

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Start Trial British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA) 2033-09-09 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA) 2033-09-09 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial British Columbia Cancer Agency Branch (CA) The University of British Columbia (CA) 2033-09-09 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,375,496

Country Patent Number Publication Date
World Intellectual Property Organization (WIPO) 2015031984 Mar 12, 2015
United States of America 2015125389 May 07, 2015
United States of America 2016367707 Dec 22, 2016
Singapore 11201601431V Mar 30, 2016
South Korea 20160054523 May 16, 2016
Japan 2016530285 Sep 29, 2016
European Patent Office 3044197 Apr 05, 2017
>Country >Patent Number >Publication Date

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Colorcon
Medtronic
Merck
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.